NCT01519869已完成2 期
Neoadjuvant Platinum-based Chemotherapy in Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Trial Protocol
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Percentage of Patients That Achieve Maximal Surgical Debulking
研究概览
简要总结
This is a prospective study to evaluate the hypothesis that platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy is associated with improved maximal surgical cytoreduction rates, comparable survival, decreased morbidity, and increased quality of life in patients with International Federation of Gynecologic Oncology stages IIIC and IV ovarian, primary peritoneal, or fallopian tube cancer when compared to historical controls and to evaluate the hypothesis that cancer induced inflammation is a predictor of poor prognosis and response to therapy in this group of ovarian cancer patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with biopsy proven stage IIIC/IV epithelial ovarian cancer, primary peritoneal, fallopian tube carcinoma. If a core biopsy is not possible, fine-needle aspirate showing adenocarcinoma is acceptable in the setting of a pelvic mass and presence of metastasis outside the pelvis measuring at least 2 cm, regional lymph-node metastasis or proof of stage IV disease, and ratio of CA 125 to CEA greater than
- •If CA 125 to CEA ratio is 25 or lower, barium enema, gastroscopy, and mammography must be negative.
- •Patients must have adequate:
- •Bone marrow function: Absolute neutrophil count (ANC) greater than or equal to 1,500/μl, equivalent to Common Toxicity Criteria for Adverse Events v3.0(CTCAE) Grade
- •This ANC cannot have been induced or supported by granulocyte colony stimulating factors.
- •Platelets greater than or equal to 100,000/μl, CTCAE Grade 0-
- •Renal function: Creatinine ≤1.5 x institutional upper limit of normal ULN), CTCAE Grade
- •Hepatic function: Bilirubin ≤ 1.5 x ULN, CTCAE Grade 1.SGOT and alkaline phosphatase ≤ 2.5 x ULN, CTCAE Grade
- •Neurologic function: Neuropathy (sensory and motor) less than or equal to CTCAE Grade
- •Blood coagulation parameters: PT such that international normalized ratio (INR) is ≤ 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin for management of venous thrombosis) and a PTT <1.2 x ULN.
- •Patients must have a World Health Organization Performance Status ≤
- •Patients must be a candidate for surgery.
- •An approved informed consent must be signed by the patient.
排除标准
- •Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease.
- •Patients who have received prior chemotherapy for any abdominal or pelvic tumor are excluded. Patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease.
- •Patients with a known synchronous primary endometrial cancer, or a past history of primary endometrial cancer, are excluded, unless all of the following conditions are met: Stage not greater than IA, no more than superficial myometrial invasion, without vascular or lymphatic invasion, no poorly differentiated subtypes (including papillary serous, clear cell or other FIGO Grade 3 lesions).
- •With the exception of non-melanoma skin cancer and other specific malignancies noted above, patients with other invasive malignancies who had (or have) any evidence of the other cancer present within the last five years or whose previous cancer treatment contraindicates this therapy are excluded.
- •Patients with acute hepatitis or active infection that requires parenteral antibiotics are excluded.
- •Patients with World Health Organization Performance Status of 3 or
- •Patients who are pregnant or nursing.
- •Patients under the age of
- •Patients with a pelvic mass of any size that is causing pain, or other subjective symptoms that are intolerable to the patient.
- •Patients who are not candidates for interval surgical debulking secondary to significant medical comorbidities.
研究组 & 干预措施
neoadjuvant chemotherapy
Experimental
platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy
干预措施: neoadjuvant chemotherapy (Drug)
结局指标
主要结局
Percentage of Patients That Achieve Maximal Surgical Debulking
时间窗: 5 years
Percentage of patients that achieve maximal surgical debulking as defined by no gross residual disease following a Simon's 2-stage design.
次要结局
未报告次要终点
研究者
Rachel Miller
Assistant Professor, Obstetrics and Gynecology
University of Kentucky
研究点 (1)
Loading locations...
相似试验
终止
2 期
Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast CancerBreast NeoplasmsNCT01167192Washington University School of Medicine10
已完成
2 期
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)Lung CancerNCT01443078Memorial Sloan Kettering Cancer Center42
招募中
3 期
Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node SpreadCervical Cancer TNM Staging Regional Lymph Nodes (N)NCT03534713University Hospital, Toulouse310
Unknown
1 期
Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck CancerHead and Neck NeoplasmsNCT00982436University of Vermont37
进行中（未招募）
不适用
Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast CancerInvasive Breast CarcinomaNCT04897009Mayo Clinic38